Key result
Rare variants in MuRF1 and MuRF2 were more prevalent in HCM patients than controls (MuRF1: 2.2% vs 0.3%, p=0.04; MuRF2: 3.7% vs 0.7%, p=0.007) and associated with greater wall thickness.
Why the study?
Are rare variants in MuRF genes associated with hypertrophic cardiomyopathy and its clinical severity?
Case-Control (n=901)
Are rare variants in MuRF genes associated with hypertrophic cardiomyopathy and its clinical severity?
Absolute Event Rate: 2.2% vs 0.3%
p-value: p=0.04
Rare variants in MuRF1 and MuRF2 are associated with hypertrophic cardiomyopathy and may act as modifier genes leading to more severe clinical manifestations such as increased left ventricular wall thickness.
No takes yet. Share an insight, caveat, or question.
Supports MuRF variants as potential HCM modifiers; hypothesis-generating and should not yet change practice.
Su et al. (2014) conducted a case-control in Hypertrophic cardiomyopathy (n=901). Rare variants in MuRF1 and MuRF2 vs. Healthy controls was evaluated on Prevalence of rare variants in MuRF1 (p=0.04). Rare variants in MuRF1 and MuRF2 were more prevalent in HCM patients than controls (MuRF1: 2.2% vs 0.3%, p=0.04; MuRF2: 3.7% vs 0.7%, p=0.007) and associated with greater wall thickness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: